Clinical Trial

18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients

Recruiting
View on ClinicalTrials.gov →
Summary
Carotid atherosclerotic plaque rupture is the main cause of ischemic stroke attacks, and early and precise assessment of plaque vulnerability can prevent ischemic stroke. High-resolution MRI can reflect vulnerable plaque features such as thin fibrous caps and large lipid cores, but cannot assess their metabolic information; Fibro-activated proteins (FAPs) of PET are specifically expressed in atherosclerosis and suggest vulnerable plaques by reflecting inflammation-induced fibrosis. The aim of this study was to apply 18F FDG\&68Ga-FAPI PET/MR imaging to investigate the vulnerability of carotid atherosclerotic plaques, to obtain quantitative evaluation indexes of active fibrosis within carotid plaques, and to clarify the PET/MR characteristics of unstable plaques in carotid arteries
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-26.
Trial Details
NCT Number NCT07004673
Lead Sponsor Ruijin Hospital
Collaborators: National Natural Science Foundation of China
Conditions Carotid Artery Plaque, Ischemic Stroke, PET / MR
Enrollment 100 participants
Start Date 2025-04-12
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-05